The Latin America, Middle East and Africa Minimal Residual Disease Testing Market should witness market growth of 19.4% CAGR during the forecast period (2022-2028).
After primary cancer therapy, potential MRD diagnoses are essential for making intelligent individual and long-term clinical decisions. Additionally, MRD diagnosis effectiveness is critical for healthcare insurance firms to successfully provide financial aid to cancer survivors around the world.
Finally, the successful implementation of a particular cancer treatment regimen depends on the measurement of therapeutic results. As a result, MRD testing is being employed more frequently as the final stage of end-point analysis in several clinical trial studies for oncology-based research. It also efficiently captures variances in outcomes resulting from unique genetic traits.
In the coming years, major participants in the minimal residual disease testing market would have the opportunity for expansion in developing economies. This can be linked to the growing elderly population, the rising frequency of hematologic cancers, the rising cost of healthcare per person, and the development of the healthcare system.
In this region, leukemia is one of the leading causes of cancer mortality among children. As a result, it is considered the main health challenge. The restricted access to healthcare, socioeconomic disparities, and the significant lack of economic resources in the region lowers the survival rates that are conventionally witnessed in high-income nations. The delay in diagnosis, lack of supportive care, dearth of pediatric oncologists and nurses, and frequent treatment abandonment also result in increasing children mortality proportions in the region.
The Brazil market dominated the LAMEA Minimal Residual Disease Testing Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $50.3 million by 2028.The Argentina market is experiencing a CAGR of 20% during (2022-2028). Additionally, The UAE market would display a CAGR of 19.1% during (2022-2028).
Based on Application, the market is segmented into Hematological Malignancies, Leukemia, Lymphoma, Solid Tumors and Others. Based on End-user, the market is segmented into Hospitals & Specialty Clinics, Diagnostic Laboratories, Academic & Research Institutes and Others. Based on Technology, the market is segmented into Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Flow Cytometry and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Bio-Rad Laboratories, Inc., Guardant Health, Inc., Invitae Corporation (ArcherDX, Inc.), Bio-Techne Corporation, F. Hoffmann-La Roche Ltd., ICON plc (MolecularMD Corporation), Natera, Inc., Sysmex Corporation, Laboratory Corporation of America Holdings, and Invivoscribe, Inc.
After primary cancer therapy, potential MRD diagnoses are essential for making intelligent individual and long-term clinical decisions. Additionally, MRD diagnosis effectiveness is critical for healthcare insurance firms to successfully provide financial aid to cancer survivors around the world.
Finally, the successful implementation of a particular cancer treatment regimen depends on the measurement of therapeutic results. As a result, MRD testing is being employed more frequently as the final stage of end-point analysis in several clinical trial studies for oncology-based research. It also efficiently captures variances in outcomes resulting from unique genetic traits.
In the coming years, major participants in the minimal residual disease testing market would have the opportunity for expansion in developing economies. This can be linked to the growing elderly population, the rising frequency of hematologic cancers, the rising cost of healthcare per person, and the development of the healthcare system.
In this region, leukemia is one of the leading causes of cancer mortality among children. As a result, it is considered the main health challenge. The restricted access to healthcare, socioeconomic disparities, and the significant lack of economic resources in the region lowers the survival rates that are conventionally witnessed in high-income nations. The delay in diagnosis, lack of supportive care, dearth of pediatric oncologists and nurses, and frequent treatment abandonment also result in increasing children mortality proportions in the region.
The Brazil market dominated the LAMEA Minimal Residual Disease Testing Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $50.3 million by 2028.The Argentina market is experiencing a CAGR of 20% during (2022-2028). Additionally, The UAE market would display a CAGR of 19.1% during (2022-2028).
Based on Application, the market is segmented into Hematological Malignancies, Leukemia, Lymphoma, Solid Tumors and Others. Based on End-user, the market is segmented into Hospitals & Specialty Clinics, Diagnostic Laboratories, Academic & Research Institutes and Others. Based on Technology, the market is segmented into Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Flow Cytometry and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Bio-Rad Laboratories, Inc., Guardant Health, Inc., Invitae Corporation (ArcherDX, Inc.), Bio-Techne Corporation, F. Hoffmann-La Roche Ltd., ICON plc (MolecularMD Corporation), Natera, Inc., Sysmex Corporation, Laboratory Corporation of America Holdings, and Invivoscribe, Inc.
Scope of the Study
By Application
- Hematological Malignancies
- Leukemia
- Lymphoma
- Solid Tumors
- Others
By End-user
- Hospitals & Specialty Clinics
- Diagnostic Laboratories
- Academic & Research Institutes
- Others
By Technology
- Polymerase Chain Reaction (PCR)
- Next-Generation Sequencing (NGS)
- Flow Cytometry
- Others
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Bio-Rad Laboratories, Inc.
- Guardant Health, Inc.
- Invitae Corporation (ArcherDX, Inc.)
- Bio-Techne Corporation
- F.Hoffmann-La Roche Ltd.
- ICON plc (MolecularMD Corporation)
- Natera, Inc.
- Sysmex Corporation
- Laboratory Corporation of America Holdings
- Invivoscribe, Inc.
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 LAMEA Minimal Residual Disease Testing Market, by Application
1.4.2 LAMEA Minimal Residual Disease Testing Market, by End User
1.4.3 LAMEA Minimal Residual Disease Testing Market, by Technology
1.4.4 LAMEA Minimal Residual Disease Testing Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. LAMEA Minimal Residual Disease Testing Market by Application
3.1 LAMEA Hematological Malignancies Market by Country
3.2 LAMEA Leukemia Market by Country
3.3 LAMEA Lymphoma Market by Country
3.4 LAMEA Solid Tumors Market by Country
3.5 LAMEA Others Market by Country
Chapter 4. LAMEA Minimal Residual Disease Testing Market by End User
4.1 LAMEA Hospitals & Specialty Clinics Market by Country
4.2 LAMEA Diagnostic Laboratories Market by Country
4.3 LAMEA Academic & Research Institutes Market by Country
4.4 LAMEA Others Market by Country
Chapter 5. LAMEA Minimal Residual Disease Testing Market by Technology
5.1 LAMEA Polymerase Chain Reaction (PCR) Market by Country
5.2 LAMEA Next-Generation Sequencing (NGS) Market by Country
5.3 LAMEA Flow Cytometry Market by Country
5.4 LAMEA Others Market by Country
Chapter 6. LAMEA Minimal Residual Disease Testing Market by Country
6.1 Brazil Minimal Residual Disease Testing Market
6.1.1 Brazil Minimal Residual Disease Testing Market by Application
6.1.2 Brazil Minimal Residual Disease Testing Market by End User
6.1.3 Brazil Minimal Residual Disease Testing Market by Technology
6.2 Argentina Minimal Residual Disease Testing Market
6.2.1 Argentina Minimal Residual Disease Testing Market by Application
6.2.2 Argentina Minimal Residual Disease Testing Market by End User
6.2.3 Argentina Minimal Residual Disease Testing Market by Technology
6.3 UAE Minimal Residual Disease Testing Market
6.3.1 UAE Minimal Residual Disease Testing Market by Application
6.3.2 UAE Minimal Residual Disease Testing Market by End User
6.3.3 UAE Minimal Residual Disease Testing Market by Technology
6.4 Saudi Arabia Minimal Residual Disease Testing Market
6.4.1 Saudi Arabia Minimal Residual Disease Testing Market by Application
6.4.2 Saudi Arabia Minimal Residual Disease Testing Market by End User
6.4.3 Saudi Arabia Minimal Residual Disease Testing Market by Technology
6.5 South Africa Minimal Residual Disease Testing Market
6.5.1 South Africa Minimal Residual Disease Testing Market by Application
6.5.2 South Africa Minimal Residual Disease Testing Market by End User
6.5.3 South Africa Minimal Residual Disease Testing Market by Technology
6.6 Nigeria Minimal Residual Disease Testing Market
6.6.1 Nigeria Minimal Residual Disease Testing Market by Application
6.6.2 Nigeria Minimal Residual Disease Testing Market by End User
6.6.3 Nigeria Minimal Residual Disease Testing Market by Technology
6.7 Rest of LAMEA Minimal Residual Disease Testing Market
6.7.1 Rest of LAMEA Minimal Residual Disease Testing Market by Application
6.7.2 Rest of LAMEA Minimal Residual Disease Testing Market by End User
6.7.3 Rest of LAMEA Minimal Residual Disease Testing Market by Technology
Chapter 7. Company Profiles
7.1 Bio-Rad Laboratories, Inc.
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expenses
7.2 Guardant Health, Inc.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Regional Analysis
7.2.4 Research & Development Expenses
7.2.5 Recent strategies and developments:
7.2.5.1 Partnerships, Collaborations, and Agreements:
7.2.5.2 Product Launches and Product Expansions:
7.3 Invitae Corporation (ArcherDX, Inc.)
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Regional Analysis
7.3.4 Research & Development Expenses
7.3.5 Recent strategies and developments:
7.3.5.1 Partnerships, Collaborations, and Agreements:
7.4 Bio-Techne Corporation
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Segmental and Regional Analysis
7.4.4 Research & Development Expenses
7.5 F. Hoffmann-La Roche Ltd.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental and Regional Analysis
7.5.4 Research & Development Expense
7.5.5 Recent strategies and developments:
7.5.5.1 Approvals & Trails:
7.6 ICON plc (MolecularMD Corporation)
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Regional Analysis
7.6.4 Recent strategies and developments:
7.6.4.1 Partnerships, Collaborations, and Agreements:
7.7 Natera Inc.
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Regional Analysis
7.7.4 Research & Development Expenses
7.8 Sysmex Corporation
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Regional Analysis
7.8.4 Research & Development Expense
7.9 Laboratory Corporation of America Holdings
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Segmental Analysis
7.9.4 Recent strategies and developments:
7.9.4.1 Partnerships, Collaborations, and Agreements:
7.9.4.2 Product Launches and Product Expansions:
7.10. Invivoscribe, Inc.
7.10.1 Company Overview
7.10.2 Recent strategies and developments:
7.10.2.1 Partnerships, Collaborations, and Agreements:
Companies Mentioned
- Bio-Rad Laboratories, Inc.
- Guardant Health, Inc.
- Invitae Corporation (ArcherDX, Inc.)
- Bio-Techne Corporation
- F. Hoffmann-La Roche Ltd.
- ICON plc (MolecularMD Corporation)
- Natera, Inc.
- Sysmex Corporation
- Laboratory Corporation of America Holdings
- Invivoscribe, Inc.
Methodology
LOADING...
